2. Vías de señalización
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. Calcium Channel
  5. Calcium Channel Isoform

Calcium Channel

Calcium channels generate intracellular Ca2+ signals by mediating Ca2+ entry during depolarization in excitable cells[1]. These signals support neurotransmitter release, hormone release, excitation-contraction coupling, pacemaker activity, gene transcription, and synaptic plasticity[1][2]. Mechanistically, adrenergic agonists increase cardiac Ca2+ influx through PKA phosphorylation of Rad, which releases inhibition of calcium channels and enhances contractility[3]. In disease research, CACNA1C/CaV1.2 links L-type calcium channel signaling to bipolar disorder, depression, schizophrenia, autism spectrum disorders, brain function, and rodent antidepressant-like behavioral actions of LTCC inhibitors[4]. Compared with related isoforms, CaVα1 splice variants show tissue-specific expression, distinct protein-domain composition, and different pharmacological sensitivities[5]. CaV2.2 e37a is enriched in nociceptors and couples N-type calcium channels to voltage-independent G protein inhibition by µ-opioid and GABA_B receptors[6]. For experimental applications, blockers, toxins, gene-knockout models, agonists, and inhibitors help dissect channel-specific functions and guide next-generation CaV channel modulators[1][5].

Productos relacionados con Calcium Channel (913):

Cat. No. Nombre del producto Efecto Pureza
  • HY-N6850
    Calenduloside E
    		Activator 99.07%
    Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses.
  • HY-N7848
    Linoleamide
    		Inhibitor 99.4%
    Linoleamide is a linoleic acid amide. Linoleamide regulates Ca (II) ux and inhibits the erg current.
  • HY-109121
    Reldesemtiv
    		99.63%
    Reldesemtiv (CK-2127107) is a selective, orally active and next-generation fast skeletal muscle troponin activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC50 of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model.
  • HY-N0910
    Notoginsenoside Ft1
    		Agonist 99.49%
    Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8+ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca2+ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y12 receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance.
  • HY-N2877
    Annonacin
    		Inhibitor 98.09%
    Annonacin is an acetylgenin that is toxic by inhibiting the pathway of the mitochondrial complex. Annonacin increases tau phosphorylation in R406W+/+ mice. Annonacin acts as an inhibitor of the sodium/potassium and sarcoplasmic reticulum (SERCA) ATPase pumps. Annonacin has significant killing effect on ovarian cancer cell, cervical cancer cell, breast cancer cell, bladder cancer cell and skin cancer cell. Annonacin induces apoptosis through Bax and Caspase-3-related pathways.
  • HY-100712
    DPO-1
    		Inhibitor 98.39%
    DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca2+ influx in Ca2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K+ efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation.
  • HY-11013
    ZSET1446
    		Activator 98.33%
    ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.
  • HY-N6701
    Dihydrocytochalasin B
    		99.0%
    Dihydrocytochalasin B is an Actin disruptor. Dihydrocytochalasin B disrupts actin microfilament bundles, inhibits actin polymerization, and alters intracellular actin cytoskeletal structures. Dihydrocytochalasin B blocks the initiation of DNA synthesis. Dihydrocytochalasin B inhibits Calcium transport. Dihydrocytochalasin B inhibits cytokinesis and alters cell morphology. Dihydrocytochalasin B can be used in studies related to rickets.
  • HY-P10655
    Caloxin 1C2
    		Inhibitor 99.47%
    Caloxin 1C2 is a specific PMCA (plasma-membrane Ca2+-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The Ki values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca2+ transfer. Caloxin 1C2 affects coronary contractility.
  • HY-N7690
    3,5,7,3′,4′-Pentamethoxyflavone
    		Inhibitor 99.69%
    3,5,7,3’,4’-Pentamethoxyflavone is a Ca2+ channel inhibitor. 3,5,7,3’,4’-Pentamethoxyflavone can protect DNA from oxidative damage. 3,5,7,3’,4’-Pentamethoxyflavone can induce relaxation of the human corpus cavernosum through calcium mobilization-related mechanisms. 3,5,7,3’,4’-Pentamethoxyflavone can promote the expression of eNOS and cystathionine gamma lyase CSE proteins in middle-aged male rats and regulate vascular function. 3,5,7,3’,4’-Pentamethoxyflavone can be used in research related to diabetes and cardiovascular diseases.
  • HY-136460
    Calcium ionophore I
    		99.6%
    Calcium ionophore I (ETH 1001) is a selective Ca2+ ionophore for biological membranes. Calcium ionophore I can be used in Ca2+-selective microelectrodes that can be used for quantitative intracellular measurements of resting Ca2+-activities and of slowly changing Ca2+-levels.
  • HY-N8307
    Syringaresinol
    		Activator 99.66%
    Syringaresinol is a lignan-type phytochemical with anti-inflammatory activities. Syringaresinol inhibits the NF-κB and AKT signaling pathway in IL-1β-activated mouse chondrocytes. Syringaresinol increases phosphorylation of AMPK, eNOS, and intracellular Ca2+ levels in HUVECs. Syringaresinol attenuates osteoarthritis progression in mice with Destabilization of the Medial Meniscus (DMM)-induced osteoarthritis. Syringaresinol can be used for the study of osteoarthritis (OA).
  • HY-B0166S6
    L-Ascorbic acid-d2
    		99.90%
    L-Ascorbic acid-d2 is the deuterium labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a colla
  • HY-P10849
    IP3RPEP6
    		Inhibitor 98.36%
    IP3RPEP6 is an IP3R competitive inhibitor. IP3RPEP6 has the IC50 values of 9.0 μM, 3.9 μM and 4.3 μM for IP3R1, IP3R2 and IP3R3, respectively. IP3RPEP6 does not affect the Ryanodine receptor and Cx43 hemichannels. IP3RPEP6 regulates calcium signaling within cells.
  • HY-B1469
    Isosorbide
    		98.76%
    Isosorbide (D-Isosorbide), an orally active vasodilating agent that can be used for the research of heart failure and angina (chest pain). Isosorbide is also an oral hyperosmotic diuretic.
  • HY-B1237
    Suloctidil
    		Inhibitor 99.96%
    Suloctidil is an orally active calcium channel blocker and antifungal agent. Suloctidil antagonizes vasoconstriction induced by norepinephrine, angiotensin and serotonin. Suloctidil inhibits platelet function and exhibits neuroprotective effects. Suloctidil exerts inhibitory effects on Candida albicans biofilm and virulence. Suloctidil can be used in research on vasospasm relief, antithrombosis and superficial candidiasis.
  • HY-D1024A
    Coelenterazine h hydrochloride
    		99.65%
    Coelenterazine h (2-Deoxycoelenterazine) hydrochloride, a coelenterazine derivative, is a luminescent substrate for RLuc8. Coelenterazine h hydrochloride is more sensitive to Ca2+, thus providing a valuable tool for measuring small changes in Ca2+ concentrations (Ex/Em = 437/466 nm).
  • HY-N4104
    Agaric acid
    		99.45%
    Agaric acid (Agaricinic Acid) is an orally active inhibitor of adenine nucleotide translocase found in specific fungi. Agaric acid can inhibit the biofilm formation of various bacteria such as Salmonella. Agaric acid can also induce mitochondrial permeability transition, prompting mitochondria to release Ca2+, disrupting the transmembrane potential, and causing mitochondrial swelling. In addition, Agaric acid can also inhibit citrate transport in liver mitochondria and participate in the inhibition of fatty acid synthesis, affecting multiple metabolic processes.
  • HY-B1170
    Cyclandelate
    		Modulator 98.66%
    Cyclandelate is a vasodilator that can be used in the study of claudication, arteriosclerosis, Raynaud's disease, nocturnal leg cramps, and migraines.
  • HY-66010
    Cinepazide Maleate
    		Inhibitor 99.74%
    Cinepazide Maleate (MD-67350) is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide Maleate is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain?infarct et. al.